Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) Stock Price

AMLXStock

$37.46+310.22%52W

Market Cap$4.17B

P/E—

PEG Ratio—

Div yield—

Beta-0.13

AMLX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)159.32%

Price vs S&P 500 (4W)92.09%

VGM Score73.58

Book Value / Share (Quarterly)$2.15

P/TBV (Annual)2.61x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)574.28%

Cash Flow / Share (Quarterly)$-1.14

Price vs S&P 500 (YTD)203.85%

Gross Margin (TTM)82.75%

Net Profit Margin (TTM)-94.56%

EPS (TTM)$-1.43

10-Day Avg Trading Volume5.51M

EPS Excl Extra (TTM)$-1.43

Revenue Growth (5Y)127.75%

EPS (Annual)$-1.53

ROI (Annual)-47.41%

Gross Margin (Annual)63.22%

Net Profit Margin (5Y Avg)-7716.48%

Cash / Share (Quarterly)$2.25

ROA (Last FY)-43.51%

EBITD / Share (TTM)$-1.52

ROE (5Y Avg)-75.43%

Operating Margin (TTM)-99.16%

Cash Flow / Share (Annual)$-1.12

P/B Ratio10.47x

P/B Ratio (Quarterly)8.35x

Net Income / Employee (Annual)$-1,064,200

EV / Revenue (TTM)12.43x

Net Interest Coverage (TTM)-10.93x

ROA (TTM)-48.53%

EV / EBITDA (TTM)61.56x

EPS Incl Extra (Annual)$-1.53

Current Ratio (Annual)14.27x

Quick Ratio (Quarterly)11.86x

3-Month Avg Trading Volume1.99M

52-Week Price Return310.22%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$6.20

P/S Ratio (Annual)28.67x

Asset Turnover (Annual)0.45x

52-Week High$41.14

Operating Margin (5Y Avg)-7253.97%

EPS Excl Extra (Annual)$-1.53

CapEx CAGR (5Y)-1.78%

26-Week Price Return170.57%

Quick Ratio (Annual)13.98x

13-Week Price Return173.87%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)12.12x

Enterprise Value$2.46B

Revenue / Share Growth (5Y)119.26%

Asset Turnover (TTM)0.50x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-345.81%

Cash / Share (Annual)$2.88

3-Month Return Std Dev137.65%

Net Income / Employee (TTM)$-1,118,300

ROE (Last FY)-47.41%

EPS Basic Excl Extra (Annual)$-1.53

Receivables Turnover (TTM)0.00x

EV / Free Cash Flow (TTM)410.90x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.43

Receivables Turnover (Annual)0.00x

ROI (TTM)-52.92%

P/S Ratio (TTM)12.75x

Pretax Margin (5Y Avg)-7715.61%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.12

Price vs S&P 500 (52W)291.90%

Year-to-Date Return215.81%

5-Day Price Return8.66%

EPS Normalized (Annual)$-1.53

ROA (5Y Avg)-64.75%

Net Profit Margin (Annual)-345.36%

Month-to-Date Return87.84%

Cash Flow / Share (TTM)$0.04

EBITD / Share (Annual)$-1.62

Operating Margin (Annual)-360.22%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-75.43%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.43

P/TBV (Quarterly)2.13x

P/B Ratio (Annual)4.35x

Inventory Turnover (TTM)1.68x

Pretax Margin (TTM)-93.56%

Book Value / Share (Annual)$2.78

Price vs S&P 500 (13W)171.08%

Beta-0.13x

P/FCF (Annual)234.57x

Revenue / Share (TTM)$0.00

ROE (TTM)-52.92%

52-Week Low$8.46

vGradeD

gGradeA

mGradeA

vgmGradeB

AMLX Earnings Surprise History

Q2 25-0.46est. -0.45

Q3 25-0.37est. -0.43

Q4 25-0.30est. -0.34

Q1 26-0.37est. -0.34

Q2 26-0.39est. -0.36

AMLX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.33

4.35

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
AMLXAmylyx Pharmaceuticals, Inc. Common Stock	D	A	A	$37.46
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Amylyx Pharmaceuticals, Inc. Common Stock

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for amyotrophic lateral sclerosis, neurodegenerative diseases, and endocrine disorders. The company is focused on addressing unmet medical needs in these therapeutic areas.